Personalized Stem Cells reached many new milestones this year. Check out PSC’s 2021 year in review!
If you were recently diagnosed with arthritis, it may help to learn about your specific type of arthritis as well as potential treatment options.
Personalized Stem Cells’ parent company, VetStem, Inc., was recently issued a new patent that covers treating veterinary and human patients with an adipose-derived stem cell preparation. This patent, along with the entire VetStem patent portfolio, is licensed for use in PSC clinical trials.
Managing knee osteoarthritis may help to postpone or avoid surgery.
World Arthritis Day is recognized annually on October 12th in an effort to raise awareness about the impact of arthritis. An estimated 54.4 million adults in the United States have been diagnosed with arthritis.
Personalized Stem Cells announces first patient enrolled in Phase 2 Brazilian COVID-19 stem cell clinical trial licensed to Sorrento Therapeutics.
Personalized Stem Cells takes patient safety very seriously and therefore only offers FDA approved stem cell clinical trials.
A recent study concluded that people who lost more than 20% of their body weight experienced a far greater reduction in symptoms of knee osteoarthritis than those who lost less.
Though a relatively recent discovery, adipose derived stem cells are widely researched across the globe.
Osteoarthritis and rheumatoid arthritis are two very different forms of arthritis. It is important to understand the differences and to receive a correct diagnosis in order to pursue proper treatment.